| scholarly article | Q13442814 |
| P50 | author | Akseli Hemminki | Q26920981 |
| Anna Kanerva | Q64398934 | ||
| P2093 | author name string | Renee A Desmond | |
| Dung-Tsa Chen | |||
| Ralf Bützow | |||
| Mari Raki | |||
| Merja Särkioja | |||
| P2860 | cites work | Cancer cell cycles | Q29547756 |
| Cancer statistics, 2006 | Q29615133 | ||
| E2F: a link between the Rb tumor suppressor protein and viral oncoproteins | Q29618375 | ||
| Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product | Q29620421 | ||
| a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 | ||
| Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? | Q34225918 | ||
| Studies on the use of viruses in the treatment of carcinoma of the cervix | Q34240325 | ||
| Replication-selective virotherapy for cancer: Biological principles, risk management and future directions | Q34297058 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| Cellular targets for transformation by the adenovirus E1A proteins | Q34438094 | ||
| Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection | Q34562704 | ||
| Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease | Q34826559 | ||
| Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies | Q35995753 | ||
| Adenoviruses for treatment of cancer | Q36132288 | ||
| Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial | Q36180392 | ||
| Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers | Q36252226 | ||
| Targeted gene therapy for ovarian cancer | Q36386483 | ||
| Gene transfer approaches for gynecological diseases | Q36464907 | ||
| Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. | Q40264235 | ||
| Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin | Q40293332 | ||
| Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. | Q40316523 | ||
| Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer | Q40440806 | ||
| Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses | Q44654746 | ||
| AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study | Q45127753 | ||
| Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus | Q45865081 | ||
| Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy | Q45878940 | ||
| Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses | Q45886201 | ||
| Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy | Q45889153 | ||
| ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents | Q46343726 | ||
| Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan | Q46905278 | ||
| A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. | Q52537791 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents | Q64377634 | ||
| An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy | Q64380394 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| Adenoviridae | Q193447 | ||
| oncolytic virus | Q1560099 | ||
| P304 | page(s) | 166-172 | |
| P577 | publication date | 2007-10-22 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer | |
| P478 | volume | 108 |
| Q35101968 | A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients |
| Q37107332 | A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer |
| Q39491356 | An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. |
| Q34048741 | Anti-tumor function of double-promoter regulated adenovirus carrying SEA gene, in the treatment of bladder cancer |
| Q34115068 | Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. |
| Q37867584 | Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: a novel antitumor approach |
| Q34055529 | Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer |
| Q36642630 | Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus |
| Q42288961 | HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice. |
| Q39752863 | Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers |
| Q37448942 | Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time |
| Q34426949 | Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma |
| Q34405325 | Oncolytic immunotherapy: where are we clinically? |
| Q35597082 | Oncolytic virotherapy for ovarian cancer |
| Q37818831 | Oncolytic virotherapy of gynecologic malignancies |
| Q33388660 | Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors |
| Q43030471 | Role of cell surface molecules and autologous ascitic fluid in determining efficiency of adenoviral transduction of ovarian cancer cells |
| Q27307734 | SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I |
| Q47549552 | Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy |
| Q38765125 | Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model |
| Q40913003 | The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11 |
| Q39462851 | The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models |
| Q39509888 | Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus |
| Q38614156 | Tropism-modification strategies for targeted gene delivery using adenoviral vectors |
| Q99576115 | Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer |
Search more.